110 completed, 21 unknown, 16 recruiting, 6 terminated. 159 Phase 3, 24 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 159 | Completed 110, Unknown 21, Recruiting 16, Terminated 6, Withdrawn 4, Active not recruiting 1, Suspended 1 |
| Phase 2 | 24 | Completed 18, Recruiting 3, Unknown 2, Terminated 1 |
Follow Nausea: new trials by email Literature Review of Nausea trials Research Report on Nausea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Tradipitant, Placebo - Nausea and Vomiting, Obesity | Phase 3 | Recruiting | Vanda Pharmaceuticals | 280 | 2026-03-27 | 2026-04-20 |
| Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients Aprepitant 40mg, Placebo - Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Completed | Centre hospitalier de l'Université de Montréal (CHUM) | 260 | 2026-02-27 | 2026-08-27 |
| Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting Olanzapine, Metoclopramide - Nausea, Vomiting | Phase 3 | Recruiting | Affiliated Hospital of Qinghai University | 222 | 2026-02-03 | 2026-04-27 |
| Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound Auricular point stimulation plus dexamethasone, Standard pharmacologic antiemetic regimen - Nausea and Vomiting Caused by Chemotherapy | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 74 | 2025-12-12 | 2026-07-21 |
| Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide Auricular point stimulation plus dexamethasone, Standard pharmacologic antiemetic regimen - Nausea and Vomiting Caused by Chemotherapy | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 74 | 2025-12-12 | 2026-07-21 |
| Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan Auricular point stimulation plus dexamethasone, Standard pharmacologic antiemetic regimen - Nausea and Vomiting Caused by Trastuzumab Deruxtecan | Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 74 | 2025-12-12 | 2026-07-21 |
| A Clinical Study to Assess the Effectiveness of ENO Lime in Participants With Ajeerna Vyadhi (Acidity, Acid Indigestion, Indigestion, and Associated Nausea) ENO Lime - Indigestion Acid, Indigestion | Phase 3 | Completed | HALEON | 40 | 2025-08-20 | 2025-09-17 |
| Comparison of Dexmedetomidine and Dexamethasone for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy Dexamedomedine, Dexamethasone - Postoperative Nausea and Vomiting | Phase 3 | Completed | Patel Hospital, Pakistan | 68 | 2025-06-01 | 2026-02-23 |
| MELAtonin for Prevention of Postoperative Agitation and Emergence Delirium in Children Melatonin, Isotonic sodium chloride solution - Emergence Delirium | Phase 3 | Recruiting | Arash Afshari | 676 | 2025-01-21 | 2026-08-18 |
| Antiemetic Fosaprepitant To Remedy Nausea and Vomiting Fosaprepitant 150 mg, Ondansetron 4 mg - Nausea and Vomiting, Nausea | Phase 2 / Phase 3 | Recruiting | Montefiore Medical Center | 200 | 2024-11-13 | 2026-05-18 |
| Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan Olanzapine - Multiple Myeloma, Autologous Stem Cell Transplantation | Phase 3 | Recruiting | Augusta University | 172 | 2024-09-17 | 2024-11-22 |
| HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents HR20013 + dexamethasone + palonosetron placebo, Palonosetron + dexamethasone + HR20013 placebo - Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | Phase 3 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 706 | 2024-09-03 | 2025-11-17 |
| Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer Electroacupuncture, Antiemetic Therapy, Sham electroacupuncture - Electroacupuncture, Olanzapine-contained Four-drug Antiemetic | Phase 3 | Recruiting | Feixue Song | 370 | 2024-03-07 | 2024-03-21 |
| Oral Dexamethasone for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy Dexamethasone Oral, Dexamethasone - Postoperative Nausea and Vomiting | Phase 3 | Unknown | Mansoura University | 814 | 2024-03-04 | 2024-03-12 |
| Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets - Functional Dyspepsia | Phase 3 | Completed | Abbott | 564 | 2024-02-28 | 2026-04-03 |
| An Evaluation the Effect of Superhydration Versus Dextrose 10% for Prevention of Post Operative Nausea and Vomiting After Laparoscopic Cholecystectomy (Prospective Randomised Controlled Study) ringer lactate (20ml/kg), Dextrose 10% - Postoperative Nausea and Vomiting (PONV) | Phase 3 | Completed | Ain Shams University | 204 | 2024-02-25 | 2025-02-26 |
| the Efficacy and Safety of Ondansetron Oral Soluble Pellicles Ondansetron Oral Soluble Pellicles - Nausea and Vomiting | Phase 3 | Unknown | The First Affiliated Hospital of Xinxiang Medical College | 184 | 2024-02-20 | 2024-02-28 |
| Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting Aprepitant Injection, Aprepitant Injection Placebo - Postoperative Nausea and Vomiting | Phase 3 | Completed | Qilu Pharmaceutical (Hainan) Co., Ltd. | 518 | 2024-02-02 | 2025-04-23 |
| Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients Amisulpride Injection, Dexamethasone - Nausea and Vomiting, Postoperative | Phase 2 / Phase 3 | Completed | Acacia Pharma Ltd | 453 | 2024-01-18 | 2025-06-25 |
| Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer Electroacupuncture, Standard antiemetic treatment, Sham electroacupuncture - Electroacupuncture, Olanzapine-contained Four-drug Antiemetic | Phase 3 | Recruiting | Jiuda Zhao | 370 | 2024-01-16 | 2025-04-02 |
Showing 20 of 159. Sign in to see all of them.
Vomiting (90) · Postoperative Nausea and Vomiting (65) · Pain, Postoperative (16) · Pain (10) · Breast Neoplasms (9) · Neoplasms (8) · Migraine Disorders (7) · Photophobia (7) · Gastroparesis (6) · Hyperacusis (6) · Abdominal Pain (5) · Agnosia (4) · Anxiety Disorders (3) · Dyspepsia (3)
Pathological Conditions, Signs and Symptoms (159) · Signs and Symptoms (159) · Signs and Symptoms, Digestive (158) · Pathologic Processes (68) · Postoperative Complications (66) · Vomiting (53) · Neurologic Manifestations (43) · Neoplasms by Site (24) · Neoplasms (23) · Pain (23) · Nervous System Diseases (17) · Digestive System Diseases (10) · Gastrointestinal Diseases (10) · Skin and Connective Tissue Diseases (10)
Dexamethasone (40) · Ondansetron (20) · Granisetron (15) · Palonosetron (14) · Aprepitant (12) · Olanzapine (10) · Sodium Chloride (9) · Calcium Dobesilate (8) · Saline Solution (7) · casopitant (6) · Metoclopramide (5) · Gabapentin (4) · Promethazine (4) · Acetaminophen (3) · Amisulpride (3)
Acacia Pharma Ltd (6) · GlaxoSmithKline (6) · Pfizer (6) · M.D. Anderson Cancer Center (5) · Alliance for Clinical Trials in Oncology (3) · Assiut University (3) · Charleston Laboratories, Inc (3) · Merck Sharp & Dohme LLC (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Tesaro, Inc. (3) · Vanda Pharmaceuticals (3) · Balgrist University Hospital (2) · Duchesnay Inc. (2) · Evoke Pharma (2) · Gary Morrow (2)
United States (63) · China (16) · Canada (15) · France (12) · Germany (11) · Egypt (10) · Spain (8) · Italy (7) · Denmark (6) · Pakistan (6) · Poland (6) · South Korea (6) · United Kingdom (6) · Belgium (5) · Czechia (5)
Dennis Vargo, MD (3) · Alejandro Gonzalez-Ojeda, M.D., Ph.D. (2) · Hsiao-Wen Tsai, M.D. (2) · Juan Wang (2) · Moataz M Emara, MD, EDAIC (2) · Patrick Zingg, MD (2) · A. Riaz, MD (1) · Alana Koehler, MD (1) · Alex Molassiotis, MD (1) · Alex Sia (1) · Amal I. Melhem-Bertrandt, MD (1)
PMID 26272769, PMID 11773155, PMID 12145072, PMID 12377323, PMID 12562658, PMID 15680647, PMID 16198982, PMID 16436839, PMID 16849762, PMID 17043939, PMID 18448749, PMID 19135415, PMID 19428297, PMID 19805683, PMID 20842754, PMID 20843504, PMID 21182781, PMID 21436683, PMID 21851346, PMID 21872708, PMID 22184293, PMID 22286518, PMID 22343090, PMID 22546966, PMID 22915657, PMID 22972538, PMID 23041302, PMID 23062719, PMID 23244208, PMID 23510951, PMID 23635614, PMID 23811424, PMID 23887247, PMID 24015953, PMID 24438599, PMID 24882606, PMID 25037960, PMID 25052410, PMID 25563879, PMID 25761431, PMID 25884778, PMID 25900659, PMID 25921377, PMID 26032041, PMID 26272768, PMID 26289588, PMID 26844757, PMID 26921245, PMID 26952945, PMID 27082959
2014 (2), 2019 (2), U10CA037420 (2), 2009 (1), U01DK065713 (1), U10CA031946 (1), U10CA081920 (1)